HRAS, HRas proto-oncogene, GTPase, 3265

N. diseases: 698; N. variants: 29
Disease: Bladder Neoplasm ×
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0005695
Disease: Bladder Neoplasm
Bladder Neoplasm 		0.600 Biomarker disease BEFREE HRAS as a potential therapeutic target of salirasib RAS inhibitor in bladder cancer. 29901113 2018
CUI: C0005695
Disease: Bladder Neoplasm
Bladder Neoplasm 		0.600 GeneticVariation disease BEFREE These results suggest that mosaicism for oncogenic HRAS mutations may increase the risk for developing BC at a young age. 24169525 2014
CUI: C0005695
Disease: Bladder Neoplasm
Bladder Neoplasm 		0.600 GeneticVariation disease BEFREE It is evident from our study that HRAS T81C SNP moderately increases bladder cancer risk, and rare allele is a predictive marker of advanced bladder tumors. 21514184 2013
CUI: C0005695
Disease: Bladder Neoplasm
Bladder Neoplasm 		0.600 AlteredExpression disease BEFREE Analysis of HRAS gene TRR methylation showed that the methylation level of HRAS has clinical relevance (P = 0.0049, by unpaired Student's t test) with bladder cancer. 22707223 2012
CUI: C0005695
Disease: Bladder Neoplasm
Bladder Neoplasm 		0.600 Biomarker disease BEFREE These results indicate that overactivation of Ha-ras is both necessary and sufficient to induce bladder tumors along a low-grade, noninvasive papillary pathway, and they shed light on the recent findings that ras activation, via point mutation, overexpression, or intensified signaling from FGF receptor 3, occurs in 70%-90% of these tumors in humans. 17256055 2007
CUI: C0005695
Disease: Bladder Neoplasm
Bladder Neoplasm 		0.600 GeneticVariation disease BEFREE All together, co-existence of Aurora-A overexpression and Ha-ras mutation suggests a possible additively effect on the tumorigenesis of bladder cancer. 16338065 2006
CUI: C0005695
Disease: Bladder Neoplasm
Bladder Neoplasm 		0.600 Biomarker disease CTD_human High susceptibility of human c-Ha-ras proto-oncogene transgenic rats to carcinogenesis: a cancer-prone animal model. 15958052 2005
CUI: C0005695
Disease: Bladder Neoplasm
Bladder Neoplasm 		0.600 Biomarker disease BEFREE These results provide the first in vivo experimental evidence that p53 deficiency predisposes the urothelium to hyperproliferation, but is insufficient for bladder tumorigenesis; that the mere reduction of p53 dosage, as produced in transgenic mice expressing the dominant-negative p53 or in heterozygous p53 knockouts, is incapable of synergizing with Ha-ras to induce bladder tumors; and that the complete loss of p53 is a prerequisite for collaborating with activated Ha-ras to promote bladder tumorigenesis. 14737103 2004
CUI: C0005695
Disease: Bladder Neoplasm
Bladder Neoplasm 		0.600 GeneticVariation disease BEFREE HRAS1 genotype may be related to the prognosis of bladder cancer, however, because incident cases, i.e., newly diagnosed cases had a higher frequency of rare alleles than did prevalent cases, i.e., cases already existing at the time of recruitment. 12115522 2002
CUI: C0005695
Disease: Bladder Neoplasm
Bladder Neoplasm 		0.600 AlteredExpression disease BEFREE Our results also suggest that, whereas EGFr and Ha-ras, both of which act in the same signal transduction cascade, stimulated urothelial hyperplasia, they were not synergistic in urothelial tumorigenesis, and EGFr overexpression can cooperate with p53 and pRB dysfunction (as occurring in SV40T transgenic mice) to promote bladder tumor growth. 12124355 2002
CUI: C0005695
Disease: Bladder Neoplasm
Bladder Neoplasm 		0.600 GeneticVariation disease BEFREE In this study, we reevaluated the frequency of Ha-ras codon 12 mutations in a series of 87 human bladder tumors using a combination of two different methods. 10767358 2000
CUI: C0005695
Disease: Bladder Neoplasm
Bladder Neoplasm 		0.600 GeneticVariation disease BEFREE Furthermore, the bladder cancer cell lines were subjected to sequence analysis to identify a point mutation in the c-H-ras gene at codon 12. 10995035 2000
CUI: C0005695
Disease: Bladder Neoplasm
Bladder Neoplasm 		0.600 GeneticVariation disease BEFREE The c-Ha-ras-1 locus was studied by Southern blotting in white blood cells and tumor samples obtained from 126 patients with bladder cancer (74 Ta-T1 and 52 T2-T4). 8583569 1996
CUI: C0005695
Disease: Bladder Neoplasm
Bladder Neoplasm 		0.600 AlteredExpression disease BEFREE Lack of influence of c-Ha-ras expression on the drug sensitivity of human bladder cancer histocultured in three-dimensions. 8352563 1993
CUI: C0005695
Disease: Bladder Neoplasm
Bladder Neoplasm 		0.600 Biomarker disease CTD_human Activating missense mutations in Ha-ras-1 genes in a malignant subset of bladder lesions induced by N-butyl-N-(4-hydroxybutyl)nitrosamine or N-[4-(5-nitro-2-furanyl)-2-thiazolyl]formamide. 2278634 1990
CUI: C0005695
Disease: Bladder Neoplasm
Bladder Neoplasm 		0.600 Biomarker disease CTD_human Oncogene expression of FANFT- or BBN-induced rat urothelial cells. 2228319 1990
CUI: C0005695
Disease: Bladder Neoplasm
Bladder Neoplasm 		0.600 GeneticVariation disease BEFREE c-Ha-ras-1 alleles in bladder cancer, Wilms' tumour and malignant melanoma. 2892780 1988
CUI: C0005695
Disease: Bladder Neoplasm
Bladder Neoplasm 		0.600 AlteredExpression disease BEFREE Malignant properties of sublines selected from a human bladder cancer cell line that contains an activated c-Ha-ras oncogene. 3409229 1988
CUI: C0005695
Disease: Bladder Neoplasm
Bladder Neoplasm 		0.600 GeneticVariation disease BEFREE On the other hand, deletion of one Ha-ras allele was observed in 1 of 5 cases of bladder cancer and in 2 of 3 cases of renal pelvic cancer, suggesting that that deletion may be important in the development of urothelial cancer. 2889677 1987
CUI: C0005695
Disease: Bladder Neoplasm
Bladder Neoplasm 		0.600 Biomarker disease BEFREE A point mutation alters the 12th amino acid of the c-Ha-ras oncogene product p21 in a human bladder cancer cell line. 6304875 1983
CUI: C0005695
Disease: Bladder Neoplasm
Bladder Neoplasm 		0.600 CausalMutation disease CGI